KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Emergent BioSolutions (EBS) Invested Capital: 2010-2025

Historic Invested Capital for Emergent BioSolutions (EBS) over the last 16 years, with Sep 2025 value amounting to $1.3 billion.

  • Emergent BioSolutions' Invested Capital rose 5.49% to $1.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 billion, marking a year-over-year increase of 5.49%. This contributed to the annual value of $1.2 billion for FY2024, which is 22.07% down from last year.
  • Emergent BioSolutions' Invested Capital amounted to $1.3 billion in Q3 2025, which was up 3.19% from $1.2 billion recorded in Q2 2025.
  • In the past 5 years, Emergent BioSolutions' Invested Capital ranged from a high of $2.8 billion in Q4 2022 and a low of $1.2 billion during Q4 2024.
  • Over the past 3 years, Emergent BioSolutions' median Invested Capital value was $1.3 billion (recorded in 2025), while the average stood at $1.5 billion.
  • Its Invested Capital has fluctuated over the past 5 years, first grew by 27.61% in 2021, then crashed by 45.83% in 2023.
  • Over the past 5 years, Emergent BioSolutions' Invested Capital (Quarterly) stood at $2.5 billion in 2021, then grew by 13.83% to $2.8 billion in 2022, then plummeted by 45.83% to $1.5 billion in 2023, then decreased by 22.07% to $1.2 billion in 2024, then increased by 5.49% to $1.3 billion in 2025.
  • Its Invested Capital stands at $1.3 billion for Q3 2025, versus $1.2 billion for Q2 2025 and $1.3 billion for Q1 2025.